12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Glycopyrronium bromide: Phase III data

The double-blind, international Phase III GLOW1 trial in COPD patients showed that once-daily 50 µg inhaled NVA237 met the primary endpoint of significantly improving trough FEV1 from baseline to week 12 vs. placebo (p<0.001). Additionally, the incidence of adverse events was similar between treatment groups. Novartis plans to submit regulatory applications for NVA237...

Read the full 245 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >